## Abstract The original article to which this Erratum refers was published in International Journal of Cancer (2004) 110(3) 563–569 DOI: 10.1002/ijc.20170
Serologic detection of diffuse large B-cell lymphoma-associated antigens
✍ Scribed by Amanda P. Liggins; Barbara A. Guinn; Chris S. Hatton; Karen Pulford; Alison H. Banham
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- French
- Weight
- 173 KB
- Volume
- 110
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Diffuse large B‐cell lymphoma (DLBCL) accounts for 30–40% of all adult non‐Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. Our present study used the serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify DLBCL‐associated antigens. SEREX screening of testis libraries has previously identified cancer‐testis antigens (CTAs) that may act as disease‐specific targets for immunotherapy. Screening a testis cDNA expression library with serum from a DLBCL patient identified a total of 94 positive clones, representing 28 distinct antigens. Two of these antigens were novel, 8 were previously uncharacterised, and the remainder were proteins of known function. Screening of the antigens with sera from DLBCL (n = 10), acute myeloid leukaemia (AML, n = 10) and chronic myeloid leukaemia (CML, n = 10) patients, alongside normal healthy donor controls (n = 20), revealed that 7 of the antigens were recognised by DLBCL sera but not normal donor sera, whilst 2 of these antigens were also recognised by leukaemic sera. Some of the genes identified here were already known to be transcribed in DLBCL. The mRNA expression of the majority of the remaining antigens was confirmed in DLBCL cell lines using reverse‐transcriptase PCR (RT‐PCR). Our study identified a number of DLBCL associated antigens that may be suitable as prognostic/diagnostic markers and/or for the immunotherapy of haematologic malignancies. © 2004 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
B-lineage diffuse large cell lymphoma (B-DLCL) arising de novo is chatacterized by a marked degree of clinical heterogeneity. To determine whether or not the clinical heterogeneity of de novo B-DLCL is reflected by heterogeneity in the molecular features of these tumors, we investigated the pattern
## Abstract ## BACKGROUND Peripheral T‐cell lymphomas (PTCLs) are a biologically heterogeneous subgroup of lymphomas with poor prognosis. In this study, the authors analyzed the clinical behaviors of PTCLs and diffuse large B‐cell lymphoma (DLBCL). ## METHODS The authors compared the characteris
## Abstract Diffuse large B‐cell lymphoma (DLBCL) is a biologically heterogeneous disease for which the current approach to treatment is only successful for 50% of patients. The prognostic value of various clinical and biological factors in predicting treatment outcome is discussed in this paper. A